Story perspectives

Colossal Biosciences Acquires ViaGen to Boost Conservation Efforts

11/5/2025

28 2

Summary

Story summary

Colossal Biosciences has acquired ViaGen, a Texas-based pet cloning company, marking its first acquisition since 2021.
Colossal aims to revive extinct species such as the woolly mammoth and preserve endangered species through genetic technologies.
ViaGen is known for cloning pets and has cloned endangered species, including the black-footed ferret.
Ben Lamm, Colossal's chief executive officer, says the acquisition will advance conservation and retain ViaGen's pet-cloning business.

1 of 1

Story summary

Colossal Biosciences has acquired ViaGen, a Texas-based pet cloning company, marking its first acquisition since 2021.
Colossal aims to revive extinct species such as the woolly mammoth and preserve endangered species through genetic technologies.
ViaGen is known for cloning pets and has cloned endangered species, including the black-footed ferret.
Ben Lamm, Colossal's chief executive officer, says the acquisition will advance conservation and retain ViaGen's pet-cloning business.